Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Autor:
Sara M. Tolaney, Eric P. Winer, Rebecca Rees, William T. Barry, Shom Goel, Lorenzo Trippa, Laura Spring, Sonia Pernas, Rie K. Tahara, Erica L. Mayer, Chelsea Andrews, Zhenying Tan-Wasielewski, Aditya Bardia
Publikováno v:
Clinical Breast Cancer. 19:399-404
Background Signaling through the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway can mediate therapeutic resistance in HER2-positive breast cancer. Preclinical studies have demonstrated that CDK4/6 inhibitors can resensitize resistant HER2-positive
Autor:
Elisavet Paplomata, Keerthi Gogineni, Zhengjia Chen, Xiaoxian Li, Yuan Liu, Virginia G. Kaklamani, Ruth O'Regan, Carlos S. Moreno, Amelia Zelnak, Cesar A. Santa-Maria
Publikováno v:
Clinical Breast Cancer. 19:188-196
Background Increased signaling through growth factor receptor pathways, including HER2, plays a role in resistance to endocrine therapy (ET) in patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). Inhibition of mechanistic tar
Autor:
Rahul Ladwa, Shivanshan Pathmanathan, Jasotha Sanmugarajah, Natasha Woodward, David Wyld, Timothy Kalas
Publikováno v:
Clinical Breast Cancer. 18:e1181-e1187
Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain
Autor:
Alba Fiorentino, Francesca Di Salvo, F. Bonfantini, Valentina Maria Riboldi, Riccardo Valdagni, Milena Sant, V. Cosentino, Laura Lozza, Massimiliano Gennaro, Maria De Santis, Emanuele Pignoli, Serena Di Cosimo, Giulia Bianchi
Publikováno v:
Clinical Breast Cancer. 18:e363-e371
The purpose of this study was to examine the impact of trastuzumab on acute skin and cardiac toxicity in patients with breast cancer treated with chemotherapy with or without trastuzumab and adjuvant whole breast hypofractionated radiotherapy (hypo-R
Autor:
Allison M. Deal, Julia M. Benbow, Carey K. Anders, Louisa A. Mounsey, Kevin Keith, Matthew G. Ewend, E. Claire Dees, Timothy M. Zagar, Shlomit S. Shachar, Lisa A. Carey
Publikováno v:
Clinical Breast Cancer. 18:29-37
Background Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for advanced HER2–positive breast cancer, we studied the natural history of patients with HER2–positive breast cancer brain metastases (BCBM)
Publikováno v:
Clinical Breast Cancer. 17:e37-e41
Autor:
Andrea Fontana, Lucia Del Mastro, Matteo Lambertini, S. Pastorino, Chiara Molinelli, Giuseppe Naso, Francesca Poggio, Valentina Magri, Claudia Bighin, Giuseppe Buono, Grazia Arpino, Loredana Miglietta, Alessandra Fabi, Daniele Presti, Francesco Boccardo, Alessia D'Alonzo, Chiara Dellepiane, Francesco Cognetti, Silvia Mura, Eva Blondeaux, Benedetta Conte
Publikováno v:
Clinical breast cancer. 20(2)
Background T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data
Autor:
Yoshinori Ito, Futoshi Akiyama, Rie Horii, Takuji Iwase, Shunji Takahashi, Kazuhiro Araki, Ippei Fukada
Publikováno v:
Clinical Breast Cancer. 15:432-439
Background Multiple anti-HER2 therapies have improved the outcome for patients with HER2-positive breast cancer. However, optimal management has yet to be established for lapatinib (LAP)- and trastuzumab (Tmab)-resistant disease progression. Data fro
Autor:
Martine Piccart, Volker Mobus, Investigators, Jennifer Eng-Wong, José Baselga, Thomas Suter, Giuseppe Viale, Amal Arahmani, José Bines, Emma Clark, Richard D. Gelber, Marion Procter, Eleonora Restuccia, Veerle Van Dooren, Evandro de Azambuja, Dimitrios Zardavas
Publikováno v:
Clinical Breast Cancer. 20:174-181.e3
Background The APHINITY (BIG 4-11) study showed that pertuzumab significantly improved the rates of invasive disease-free survival among patients with human epidermal growth factor receptor 2 (HER2)-positive, operable breast cancer when added to adju
Autor:
Daniel Hunt, Shukui Qin, Lori J. Goldstein, K. Tkaczuk, Kimberly L. Blackwell, Mario Campone, Khalil Zaman, Richard Bryce
Publikováno v:
Clinical breast cancer. 19(2)
Background Despite the availability of several human epidermal growth factor receptor 2 (HER2)-directed treatments, many HER2-positive (HER2+) breast cancers eventually progress because of primary or acquired resistance. Patients and Methods A 2-part